Metastatic colorectal cancer.

[1]  L. Ellis,et al.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[3]  T. Pawlik,et al.  Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases , 2007, The British journal of surgery.

[4]  P. Kim,et al.  Radiofrequency Ablation for Metachronous Liver Metastasis from Colorectal Cancer after Curative Surgery , 2007, Annals of Surgical Oncology.

[5]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[7]  D. Kerr,et al.  Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial , 2003, The Lancet.

[8]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Ellis,et al.  Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases , 2007, Cancer.

[10]  U. Haedinger,et al.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases , 2006, Acta oncologica.

[11]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  L. Mariani,et al.  Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma , 2004, Cancer.

[13]  H. Bismuth,et al.  Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors , 2000, Annals of surgery.

[14]  O. Bouché,et al.  Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[16]  L. Ellis,et al.  Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy , 2003, Journal of Gastrointestinal Surgery.

[17]  E. Cotte,et al.  Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin , 2004, The British journal of surgery.

[18]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Kwiatkowski,et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Renaud-salis,et al.  Methodologie de developpement des standards, options et recommandations diagnostiques et therapeutiques en cancerologie , 1995 .

[21]  J. Douillard,et al.  Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Haller,et al.  Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. , 1996, Journal of the National Cancer Institute.

[23]  A. Padhani,et al.  A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Plaud,et al.  Is simultaneous hepatectomy and intestinal anastomosis safe? , 1995, American journal of surgery.

[26]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Rivoire.  Peut-on rendre résécables des métastases hépatiques initialement non résécables ? Commentaire , 2003 .

[28]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Lotz,et al.  CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.

[30]  D. Kerr,et al.  Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  T. Ruers,et al.  Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[33]  W. Scheithauer,et al.  Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  H. Dienemann,et al.  Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. , 2007, The Annals of thoracic surgery.

[35]  M. Valerio,et al.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Tournigand,et al.  Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Bruce D Minsky,et al.  Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[39]  A. Adenis,et al.  Standards, Options et Recommandations pour la surveillance après traitement d’un cancer du côlon , 1998 .

[40]  M. Buyse,et al.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Ychou,et al.  Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  E. Berber,et al.  Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Renaud-salis,et al.  SOR: project methodology , 2001, British Journal of Cancer.

[44]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[45]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[46]  R. Goldberg,et al.  Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Rougier,et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Vauthey,et al.  Perioperative chemotherapy for resectable hepatic metastases , 2008, The Lancet.

[50]  R. Guimbaud.  Quelle est la place de la chimiothérapie néoadjuvante, adjuvante et palliative dans la prise en charge des métastases hépatiques d'origine colorectale ? , 2008 .

[51]  C. Tournigand,et al.  Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer -A pooled analysis of 254 patients included in 2 randomised trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  T. de Baère,et al.  Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. , 2004, Hepato-gastroenterology.

[53]  T. Conroy,et al.  XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  T. Conroy,et al.  Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. McArdle,et al.  Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial , 2002, The Lancet.

[57]  P. Sugarbaker.  Peritonectomy Procedures , 1995, Surgical oncology clinics of North America.

[58]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Abdalla,et al.  Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases , 2008, Annals of Surgical Oncology.

[60]  P. Bachellier,et al.  A Two-Stage Hepatectomy Procedure Combined With Portal Vein Embolization to Achieve Curative Resection for Initially Unresectable Multiple and Bilobar Colorectal Liver Metastases , 2004, Annals of surgery.

[61]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  C. Tournigand,et al.  Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  R. Berardi,et al.  Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[65]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  T. Baere.  Modalités et faisabilité des traitements par destruction locale des métastases hépatiques (TDLMH) , 2008 .

[67]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[68]  A. Figer,et al.  OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  W. Scheithauer,et al.  Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[73]  R. Herrmann,et al.  A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  P. Bachellier,et al.  Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative Chemotherapy , 2008, Annals of surgery.

[75]  E. Gamelin,et al.  Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.

[76]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  B. Gallix.  Quels sont les examens à réaliser dans le bilan d'extension pré-thérapeutique? Critères de qualité et résultats attendus. , 2008 .

[78]  C. Christophi,et al.  The treatment of malignancy by hyperthermia. , 1998, Surgical oncology.

[79]  L. Chiche.  Quelles métastases hépatiques sont résécables d'emblée ? , 2008 .

[80]  D. Kerr,et al.  Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  B. Nordlinger,et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.

[82]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  J. Lotz,et al.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.

[84]  S. Leach,et al.  Nonoperative Management of Primary Colorectal Cancer in Patients With Stage IV Disease , 1999, Annals of Surgical Oncology.

[85]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[86]  M. Ychou,et al.  Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  P. Catalano,et al.  High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 , 2005 .

[88]  J. Chester,et al.  Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  W. Scheithauer,et al.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[91]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Robert,et al.  Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[94]  M. Ychou,et al.  A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) , 2005 .

[95]  L. Ellis,et al.  Radiofrequency ablation of hepatic metastases. , 2002, Seminars in oncology.

[96]  T. de Baère,et al.  Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival. , 2002, Surgery.

[97]  S. Choi,et al.  Clinical Outcomes of Hepatic Resection and Radiofrequency Ablation in Patients With Solitary Colorectal Liver Metastasis , 2008, Journal of clinical gastroenterology.

[98]  A. Witkamp,et al.  Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. , 2001, Cancer treatment reviews.

[99]  A. Norman,et al.  Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases , 2003, Gut.

[100]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[101]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[102]  J. Fleshman,et al.  Liver resection for colorectal metastases. , 2004, Annals of the Royal College of Surgeons of England.

[103]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[104]  J. Hecht,et al.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  J. Bosset,et al.  Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  E. Touboul,et al.  Standards, Options et Recommandations pour la prise en charge des patients atteints d'un cancer bronchique primitif de stade I ou II traités par irradiation exclusive. , 2001 .

[107]  M. Scotté,et al.  Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? , 2004, Gastroenterologie clinique et biologique.

[108]  B. Nordlinger,et al.  Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases , 2006, Annals of surgery.

[109]  J. Faivre,et al.  Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer , 1995, The British journal of surgery.